AEMD - Aethlon Medical, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.2600
-0.0200 (-7.14%)
At close: 3:36PM EDT
Stock chart is not supported by your current browser
Previous Close0.2800
Open0.2750
Bid0.2500 x 900
Ask0.3410 x 1400
Day's Range0.2500 - 0.2800
52 Week Range0.2000 - 1.7400
Volume25,095
Avg. Volume229,446
Market Cap5.121M
Beta (3Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-0.3860
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • PR Newswire

    Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Aug. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its first ...

  • PR Newswire

    Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019

    SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm Eastern time on Wednesday, August 14, 2019. Management will host a conference call on Wednesday, August 14, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • Zacks Small Cap Research

    AEMD: SeaStar Collaboration Is Intriguing, More Evidence of Exosomes’ Role in Cancer Progression

    Aethlon Medical (AEMD) reported financial results for their fiscal fourth quarter ending March 31, 2019 and provided a business update. Revenue of $80k was recorded in the quarter, representing the initial payment under AEMD’s ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September 2018 and will pay a total of $298.4k through ~August 2019. This revenue relates to a completed milestone, “to evaluate Hemopurifier-mediated capture of breast cancer exosomes”.

  • PR Newswire

    Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

    SAN DIEGO , July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its fiscal ...

  • ACCESSWIRE

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 1, 2019 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 1, 2019 at 4:30 PM Eastern ...

  • PR Newswire

    Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

    SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients. Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar's platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market.  Each company's cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.

  • PR Newswire

    Aethlon Medical To Release Fiscal Year End Financial Results and Host Conference Call on July 1, 2019

    SAN DIEGO, June 19, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for fiscal year 2019, ended March 31, 2019, at 4:15pm Eastern time on Monday, July 1, 2019. Management will host a conference call on Monday, July 1, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • PR Newswire

    Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies

    PHOENIX, May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix. Study participants will include former athletes who may have experienced repeated head impacts, such as former NFL players, as well as controls, those who played sports such as baseball that usually do not have significant head impacts.

  • Aethlon Medical Releases Shareholder Update
    PR Newswire

    Aethlon Medical Releases Shareholder Update

    SAN DIEGO, April 17, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D. With Chuck and the board's support and advice, our team is now working on executing a plan to advance Aethlon's unique Hemopurifier through clinical trials and regulatory approvals, toward ultimate commercialization as quickly and efficiently as possible.  This process should be accelerated by the FDA's designation of the Hemopurifier as a "Breakthrough Device" for both viral diseases and cancer.

  • How Financially Strong Is Aethlon Medical, Inc. (NASDAQ:AEMD)?
    Simply Wall St.

    How Financially Strong Is Aethlon Medical, Inc. (NASDAQ:AEMD)?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Aethlon Medical, Inc. (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$16m. While investors primarily fo...

  • PR Newswire

    Aethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs

    SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs.  Ms. Boswell has over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, most recently as Director, Quality Assurance and Regulatory Affairs at ZOLL Data Systems, Inc.

  • Zacks Small Cap Research

    AEMD: Eventual FDA Cancer Indication Is A Realistic Outcome

    Aethlon (AEMD) reported financial results for their fiscal third quarter ending December 31st and provided a business update.  While we had modeled an initial payment under their ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September and will pay a total of $298.4k through ~August 2019, initial revenue is now expected to be recognized in the current (i.e.

  • PR Newswire

    Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third ...

  • PR Newswire

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019

    SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019. Management will host a conference call on Monday, February 11, 2019 at 4:30 pm eastern time to review financial results and recent corporate developments. International callers should call 1-412-317-5442.

  • GlobeNewswire

    Market Trends Toward New Normal in Roper Technologies, The AES, D.R. Horton, Forrester Research, Aethlon Medical, and CyberOptics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 18, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire

    Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer

    SAN DIEGO, Dec. 13, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today the appointment of Timothy C. Rodell, M.D., FCCP, as Interim Chief Executive Officer, effective as of December 10, 2018.  Dr. Rodell joins Aethlon from GlobeImmune, Inc. where he was President, and Chief Executive Officer and a member of their board of directors prior to the shareholder majority acquisition of the company.  Dr. Rodell brings an impressive record of results in global, strategic and operational roles to Aethlon.  Dr. Rodell succeeds James Joyce, who will serve as a consultant to Aethlon during the transition.

  • ACCESSWIRE

    Today’s Research Reports on Stocks to Watch: Arsanis and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Biotech stocks Arsanis and Aethlon Medical were both seeing big gains on Tuesday on positive developments. Arsanis and privately held X4 Pharmaceuticals have agreed to merge and Aethlon announced it had received Breakthrough Device designation from FDA for their Hemopurifier in the treatment of cancer.

  • Zacks Small Cap Research

    AEMD: Breakthrough Device Designation Granted for Cancer Therapy. Could Be Game-Changer for AEMD

    By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Breakthrough Device Designation Granted for Cancer Therapy This morning Aethlon (NASDAQ:AEMD) announced that they received Breakthrough ...

  • ACCESSWIRE

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • PR Newswire

    Aethlon Medical's Cancer Therapy Receives "Breakthrough Device" Designation from the U.S. Food and Drug Administration

    SAN DIEGO, Nov. 27, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® for the treatment of cancer.  The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses. FDA's Breakthrough Device program was established under the 21st Century Cures Act to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

  • Zacks Small Cap Research

    AEMD: Pivot Towards Cancer Makes Sense. FDA Filing For Breakthrough Device in Cancer

    Aethlon (AEMD) reported financial results for their fiscal second quarter ending September 30th and provided an operational update. As we had expected, no revenue was generated in the quarter – we do, however anticipate that revenue will return in fiscal Q3 and reflect initial progress under the recently awarded NCI grant evaluating Hemopurifier in the removal of breast cancer derived exosomes from the blood.

  • GlobeNewswire

    Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire

    Aethlon Medical Announces Second Quarter Fiscal Year 2019 Results

    SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ...

  • PR Newswire

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018

    SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for ...